Figure 1 | Scientific Reports

Figure 1

From: Quantifying cell death induced by doxorubicin, hyperthermia or HIFU ablation with flow cytometry

Figure 1

Schematic depicting the use of an extracorporeal USgFUS device (JC-200, Chongqing Haifu Medical Technology Co., Ltd.) and implanted thermistor for targeted LTLD delivery to liver tumours in the TARDOX study, Oxford, UK. RIGHT: LTLD was infused intravenously prior to FUS and biopsies of the target tumour were taken before and after infusion and finally after FUS exposure. LEFT: illustrative thermistor trace obtained for the first patient treated, demonstrating the approximate range of sub-ablative levels of hyperthermia sought (39.5–42 °C) centrally within the target tumour.

Back to article page